SAGE Therapeutics is a neuroscience-focused company developing therapies to treat CNS specialty and orphan diseases. The company has identified several product opportunities with clear and accelerated paths to regulatory approval. SAGE's initial pipeline includes programs in status epilepticus, anesthesia, Fragile X Syndrome and traumatic brain injury, where CNS drugs poorly address the areas of most urgent patient need and are often accompanied by considerable side effects. The company's robust allosteric modulator chemistry platform - called the Positive and Negative Allosteric Modulator (PANAM) platform - has generated multiple new chemical entities supported by promising preclinical data with the potential to lead to products with multiple indications over the next several years. SAGE Therapeutics is a private company launched in 2011 by a proven team of R&D leaders, renowned CNS experts and Third Rock Ventures.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/16/13 | $20,000,000 | Series B |
ARCH Venture Partners Third Rock Ventures | undisclosed |
| 03/13/14 | $38,000,000 | Series C |
ARCH Venture Partners EcoR1 Capital Foresite Capital Management OrbiMed Advisors Third Rock Ventures | undisclosed |
